nintedanib
![Tvardi Therapeutics, First patient dosed, nintedanib, STAT3 inhibitors, idiopathic pulmonary fibrosis TTI-101](https://pharmtales.com/wp-content/uploads/2023/09/Tvardi-Therapeutics-Begins-Phase-2-Trial-for-Novel-IPF-Treatment.jpg)
Tvardi Therapeutics Begins Phase 2 Trial for Novel IPF Treatment
Anika Sharma
Tvardi Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing STAT3 inhibitors, has exciting news to share. They’ve initiated the dosing ...